Barrington analyst Michael Petusky raised the firm’s price target on Merit Medical to $98 from $96 and keeps an Outperform rating on the shares following the company’s “strong” Q4 results and FY24 guidance. Merit’s new long range plan forecasts 5%-7% top-line growth annually and $400M in free cash flow generation during the 2024-2026 timeframe, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MMSI:
- Merit Medical Systems Unveils Growth Plans in Earnings Call
- Merit Medical Reports Results For Fourth Quarter and Year Ended December 31, 2023 – Issues Fiscal Year 2024 Guidance
- Merit Medical Introduces “Continued Growth Initiatives” Program and Financial Targets for Three-Year Period Ending December 31, 2026
- MMSI Earnings this Week: How Will it Perform?
- Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System
